Effects of the Peroxisome Proliferator-Activated Receptor-&#947; Agonist Pioglitazone on Peripheral Vessel Function and Clinical Parameters in Nondiabetic Patients: A Double-Center, Randomized Controlled Pilot Trial | Zendy

Marian Christoph | Zendy; Joerg Herold | Zendy; Anna Berg-Holldack | Zendy; Thomas Rauwolf | Zendy; Tjalf Ziemssen | Zendy; Alexander Schmeißer | Zendy; Sönke Weinert | Zendy; Bernd Ebner | Zendy; Karim Ibrahim | Zendy; Ruth H. Strasser | Zendy; Ruediger C. BraunDullaeus | Zendy

Open Access

Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone on Peripheral Vessel Function and Clinical Parameters in Nondiabetic Patients: A Double-Center, Randomized Controlled Pilot Trial

Author(s) -

Marian Christoph,

Joerg Herold,

Anna Berg-Holldack,

Thomas Rauwolf,

Tjalf Ziemssen,

Alexander Schmeißer,

Sönke Weinert,

Bernd Ebner,

Karim Ibrahim,

Ruth H. Strasser,

Ruediger C. BraunDullaeus

Publication year - 2015

Publication title -

cardiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.547

H-Index - 63

eISSN - 1421-9751

pISSN - 0008-6312

DOI - 10.1159/000376570

Subject(s) - pioglitazone , pulse wave velocity , medicine , placebo , endocrinology , agonist , peroxisome proliferator activated receptor , urology , cardiology , receptor , type 2 diabetes , diabetes mellitus , pathology , blood pressure , alternative medicine

Despite the advanced therapy with statins, antithrombotics, and antihypertensive agents, the medical treatment of atherosclerotic disease is less than optimal. Therefore, additional therapeutic antiatherosclerotic options are desirable. This pilot study was performed to assess the potential antiatherogenic effect of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in nondiabetic patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research